BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Astronomer captures 2 meteors slamming into the moon (video) - 2Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients
- 3Top 15 Supportable Design Brands Coming out on top
- 4Hostile to Maturing Skincare Items to Rejuvenate Your Skin
- 5I’m a dad to an autistic child. Here’s how you can make the holidays easier for all of us.
- The Golden Globes gift bag has nearly $1 million worth of swag for some winners and presenters. What's in it?
- Dave Coulier shares new cancer diagnosis 1 year after revealing previous diagnosis
- Volcanic eruption led to the Black Death, new research suggests
- Gen Z workplace stereotypes were TV’s favorite punchline in 2025
- The Best Cell phone Brands for Tech Lovers
- UK forecast to face weaker growth and higher inflation from Iran war
- Oil magnate’s Venezuela detainment spooks industry
- A definitive Manual for Well known Fragrances
- These Are the Journalists Israel Has Killed Since the Start of the Iran War
